BioNTech SE (BNTX)
96.73
+0.33
(+0.34%)
USD |
NASDAQ |
Sep 11, 16:00
96.87
+0.14
(+0.14%)
After-Hours: 20:00
BioNTech Enterprise Value : 7.766B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 7.766B |
| September 10, 2026 | 7.683B |
| September 09, 2026 | 8.118B |
| September 08, 2026 | 8.251B |
| September 04, 2026 | 9.532B |
| September 03, 2026 | 9.311B |
| September 02, 2026 | 9.545B |
| September 01, 2026 | 9.076B |
| August 31, 2026 | 8.992B |
| August 28, 2026 | 9.109B |
| August 27, 2026 | 11.45B |
| August 26, 2026 | 11.74B |
| August 25, 2026 | 12.12B |
| August 24, 2026 | 11.81B |
| August 21, 2026 | 12.75B |
| August 20, 2026 | 11.32B |
| August 19, 2026 | 11.88B |
| August 18, 2026 | 6.766B |
| August 17, 2026 | 6.478B |
| August 14, 2026 | 6.852B |
| August 13, 2026 | 6.608B |
| August 12, 2026 | 6.764B |
| August 11, 2026 | 6.779B |
| August 10, 2026 | 6.779B |
| August 07, 2026 | 6.998B |
| Date | Value |
|---|---|
| August 06, 2026 | 6.375B |
| August 05, 2026 | 6.623B |
| August 04, 2026 | 6.415B |
| August 03, 2026 | 6.641B |
| July 31, 2026 | 6.221B |
| July 30, 2026 | 6.792B |
| July 29, 2026 | 6.817B |
| July 28, 2026 | 6.691B |
| July 27, 2026 | 6.349B |
| July 24, 2026 | 5.907B |
| July 23, 2026 | 6.593B |
| July 22, 2026 | 6.535B |
| July 21, 2026 | 6.661B |
| July 20, 2026 | 6.618B |
| July 17, 2026 | 6.447B |
| July 16, 2026 | 6.467B |
| July 15, 2026 | 6.575B |
| July 14, 2026 | 6.176B |
| July 13, 2026 | 6.093B |
| July 10, 2026 | 6.450B |
| July 09, 2026 | 6.824B |
| July 08, 2026 | 6.962B |
| July 07, 2026 | 7.153B |
| July 06, 2026 | 7.063B |
| July 02, 2026 | 7.971B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 53.59B |
| Biodexa Pharmaceuticals Plc | -- |
| MediGene AG | -- |
| NuCana Plc | -19.30M |
| InflaRx NV | 127.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -954.35M |
| Revenue (Quarterly) | 122.78M |
| Total Expenses (Quarterly) | 1.077B |
| EPS Diluted (Quarterly) | -3.799 |
| Gross Profit Margin (Quarterly) | -169.3% |
| Profit Margin (Quarterly) | -777.3% |
| Earnings Yield | -8.11% |
| Normalized Earnings Yield | -4.429 |